Estudo de braço único fase 2 | Rituximabe, lenalidomida e ibrutinibe em pacientes com linfoma de grandes células B recém-diagnosticado.

Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

Comentário no Twitter

In a phase II study in 60 pts with newly diagnosed DLBCL, the ORR after 2 cycles of rituximab, lenalidomide & ibrutinib was 86.2%, with a CR rate of 94.5% after a further 6 cycles together with standard chemo; 2-yr PFS & OS were 91.3% & 96.6%, respectively https://t.co/lvNs8DFSYp

— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022